Category: Medical
-
Renaissance Surgical Arts at Newport Harbor Awarded Accreditation from The Joint Commission
freeNewsArticles Story Summary: COSTA MESA, Calif. — Renaissance Surgical Arts at Newport Harbor today announced that it has met or exceeded compliance with the Joint Commission’s national standards for health care quality and safety, earning the Joint Commission’s Gold Seal of Approval. This is the second accreditation for Renaissance, the multispecialty ambulatory surgery center opened…
-
Sher Institute to Donate Free IVF Treatments at Upcoming Seminars – Dallas and Peoria Donations Part of Sher Institute ‘Giving Back’ Program
freeNewsArticles Story Summary: PEORIA, Ill. — Sher Institute for Reproductive Medicine (SIRM) announced that they will be donating free In-Vitro Fertilization (IVF) treatments at upcoming fertility education seminars in Peoria, Illinois on Wednesday, Sept. 22, and Dallas, Texas on Sunday, Sept. 26.
-
To Reach, Perchance to Kill the Cancer: A Soliloquy from Epeius Nanotechnologies Opposes that ‘Sea of Troubles’
freeNewsArticles Story Summary: SAN MARINO, Calif. — Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S. Phase I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic cancer (Molecular Therapy, 2010, 18: 435-441), which gained both…
-
Cognitive Behavior Associates Announces Going Well for Irritable Bowel Syndrome Treatment
freeNewsArticles Story Summary: BEVERLY HILLS, Calif. — Cognitive Behavior Associates, a group practice specializing in the delivery of Cognitive-Behavior Therapy, is pleased to announce a new treatment program for individuals suffering from Irritable Bowel Syndrome – Going Well(R).
-
Fertility Patients Can Now Use One Screening for Multiple Types of Genetic Diseases Before Pregnancy
freeNewsArticles Story Summary: DAVIS, Calif. — California IVF: Davis Fertility Center, Inc., working in conjunction with Gene Security Network leads the field in bringing a new test to patients that combines the detection of single-gene genetic disorders with a 24 chromosome screening.
-
ContinuLink Health Technologies, a Leader in Web-based Home Care Software Responds to Regulatory Change with Rapid Fire Solution
freeNewsArticles Story Summary: ATLANTA, Ga. — ContinuLink, a leader in Web-based home care software understands the needs of their users. Within four days of a new CMS Regulation regarding PECOS, ContinuLink users were automatically having their physicians PECOS eligibility checked though our system. ContinuLink believes they were the first system in the country to have…
-
Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate with Additional U.S. Patents
freeNewsArticles Story Summary: SAN MARINO, Calif. — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of…
-
MMDI Named Among ‘Top 50 Companies to Watch’ in the Medical Device Industry by Medical Device and Diagnostic Industry Magazine (MD+DI)
freeNewsArticles Story Summary: MINNEAPOLIS, Minn. — Minnesota Medical Development, Inc. (MMDI) today announced that it has been named as one of the ‘Top 50 Companies to Watch’ in the medical device industry by Medical Device and Diagnostic Industry (MD+DI) magazine. MMDI was chosen because of its ability to achieve success and also for its ability…
-
Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010)
freeNewsArticles Story Summary: SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled ‘Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma’ at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by…
-
Tumor-targeted Rexin-G Prolongs Survival in Gemcitabine-resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
freeNewsArticles Story Summary: SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announces the results of the clinical study entitled ‘Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer’ at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology,…